prev next front |1 |2 |3 |4 |5 |6 |7 |8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |review
In a similar phase I clinical study based on immunotherapy by WT1 in patients with breast cancer, lung cancer, myelodisplasia and acute myelocytic leukemia, Oka et al. (Proc Natl Acad Sci USA 101 (38): 13885-90, 2004) found reduction of leukemic blast cells in leukemia, a reduction in sizes and markers of other tumors and a correlation between increase and the frequency of cytotoxic T lymphocytes specific against WT1 after vaccination against it, resulting in a regression of cancer without damage to normal tissues.